Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

View Full Paper
Ask AI
Bookmark
Share

Authors

EZEmanuele ZuccaUniversity of SienaLCLuca CerianiInvestigators Research Group (United States)GCGiovannino CicconeAzienda Ospedaliera Citta' della Salute e della Scienza di Torino

Discussion

Loading...

Member takes

Implication

Trial shows R-CHOP21 increases additional treatments in primary mediastinal B-cell lymphoma, suggesting caution.

Key Points

  • Patients receiving R-CHOP21 had significantly poorer responses, with 23.8% achieving a Deauville score of 5 compared to 8.2% on other regimens.
  • The analysis indicated that R-CHOP21 resulted in higher rates of unplanned treatments, with 53.2% versus 46.9% in other groups.
  • A multinomial logistic regression confirmed that performance status and IPI score affected outcomes significantly.
  • R-CHOP21 may not be advisable as frontline therapy for primary mediastinal B-cell lymphoma due to additional treatment needs.

Cite This Study

Zucca et al. (2025) studied this question.

synapsesocial.com/papers/68c93fe601120bef803bae2ahttps://doi.org/10.1182/blood.2025028823
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach2020 · 83 citations
  2. 2R‐<scp>CHOP </scp><i>versus</i> dose‐adjusted R‐<scp>EPOCH</scp> in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis2017 · 101 citations
  3. 3End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making2018 · 91 citations
  4. 4Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group2014 · 1,686 citations
  5. 5Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial2020 · 25 citations